Investigating a new treatment for liver diseases using specific kinase inhibitors
Official title: USE OF DYRK1A/B KINASE INHIBITORS FOR THE TREATMENT OF LIVER DISEASES
Funded at Avanti Biosciences, INC. · NIH-10696380 · Data updated 2026-11-12
This study is testing a new treatment called ABI-171 for people with nonalcoholic fatty liver disease (NAFLD) and its more serious form, NASH, to see if it can help improve liver health by reducing inflammation and scarring.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Avanti Biosciences, INC. NIH-funded |
| Lab location | 1 site (East Setauket, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $349,235 |
| NIH project number | 1R43DK134232-01A1 |
| Project ID | NIH-10696380 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis.
✕Less likely to help
Patients with liver diseases caused by alcohol consumption or other non-metabolic factors may not benefit from this research.
What this research studies
This research focuses on developing a new treatment for nonalcoholic fatty liver disease (NAFLD) and its aggressive form, nonalcoholic steatohepatitis (NASH). The study will evaluate a novel compound, ABI-171, which targets specific kinases involved in liver inflammation and fibrosis. By assessing how this compound accumulates in the liver and its effects on liver health, the research aims to provide a safe and effective pharmacological option for patients suffering from these conditions. The approach includes both biochemical and cellular assays, as well as animal models to test efficacy and safety.
Why it matters
Potential benefit: If successful, this research could lead to a new medication that effectively treats liver diseases, potentially reducing the need for liver transplants.
How similar studies have gone: While there is ongoing research in this area, the specific approach using DYRK1A/B kinase inhibitors is relatively novel and has not been extensively tested in humans.
Where this research is happening
-
Avanti Biosciences, INC.
East Setauket, United States Active
Researchers
- Principal investigator: Araldi, Gian Luca — Avanti Biosciences, INC.
- Study coordinator: Araldi, Gian Luca
Related research
Other NIH-funded projects on the same topics.
-
Multimodal Tools to Diagnose and Predict Risk in Alcohol- and Metabolic-Related Liver Diseases
A Mayo Clinic-led study will use advanced computer analysis of multi-omics data and tissue images to improve diagnosis and prognosis for ALD, MASLD, and MetALD.
-
Mass spectrometry tools to find liver disease biomarkers in people with fatty liver disease
A Mayo Clinic team is testing a new, sensitive blood test method to spot biomarkers from liver disease (NAFLD/NASH) using extracellular vesicles, with the goal of better diagnosing and tracking progression.
-
Circular RNAs in Cholestatic Liver Diseases
This project looks at circular RNAs and other noncoding RNAs to understand their role in a liver disease called primary sclerosing cholangitis and how they may influence inflammation and scarring of bile ducts.
-
Molecular tricks of T cells in kids with chronic liver disease
A training program to understand why T cells don’t work well in children with chronic liver disease and how bile acids might be causing the problem.
-
Harnessing liver cell flexibility to treat cholestatic liver diseases
Aims to turn liver cells into the right type to help people with cholestatic liver diseases, including Alagille syndrome.
-
Understanding Rare Pediatric Liver Diseases inChiLDReN network
A national network study aims to grow knowledge about rare childhood liver diseases by sharing data and samples to improve care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.